Astellas Pharma, Japan's second-largest drugmaker, said on Monday it is considering how to respond to the rejection by U.S. biotech firm CV Therapeutics of its $1 billion buyout offer.
"We are reviewing our stance in light of the letter" sent to Astellas President Masafumi Nogimori by CV Therapeutics chief executive officer Louis Lange, an Astellas spokesman said.
Astellas would not comment on details, such as whether it would sweeten its $16 per share offer, he said.
More
No comments:
Post a Comment